Materias dentro de su búsqueda.
Mostrando 3,581 - 3,600 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.74s Limitar resultados
  1. 3581
    “…Here, we developed and validated a new prognostic model for predicting the risk of distant metastasis in patients with pN0-N1, hormone receptor-positive, HER2-negative (HR+/HER2−) breast cancer treated with hormone therapy alone. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2− early breast cancer
  2. 3582
    “…Later on in life, tumors arise that are mostly steroid-receptor positive, although a small subset of tumors overexpressing human epidermal growth factor 2 (HER2) and some lacking estrogen receptor, progesterone receptor (PR), and HER2 (triple negative) are present, as is the situation in humans. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Molecular Signaling of Progesterone, Growth Hormone, Wnt, and HER in Mammary Glands of Dogs, Rodents, and Humans: New Treatment Target Identification
  3. 3583
    por Fujii, Takeo, Ueno, Naoto T
    Publicado 2017
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Reply to ‘Comment on ‘Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''
  4. 3584
    “…METHODS: In this phase Ib study with 3 + 3 dose escalation design, patients with HER2-positive advanced breast cancer received pegylated liposomal doxorubicin 30 mg/m(2) intravenously on day 1 plus lapatinib 1250 (level 1) or 1500 (level 2) mg/day orally on days 1–21 of each 21-day cycle. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
  5. 3585
    “…Here, the scFv to HER2 was inserted in gB (gB(HER2)). The insertion re-targeted the virus tropism to the HER2-positive cancer cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins
  6. 3586
    “…HER2-positive breast cancer (HER2+ BC) is an aggressive subtype with a poor prognosis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss
  7. 3587
    Publicado 2017
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer [Retraction]
  8. 3588
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Randomized phase II study of nab‐paclitaxel as first‐line chemotherapy in patients with HER2‐negative metastatic breast cancer
  9. 3589
    “…Elimination of the niche-protected tumor cells was achieved with the HER2 antibody–drug conjugate T-DM1, which delivers a chemotherapeutic payload. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo
  10. 3590
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    ‘To be able to support her, I must feel calm and safe’: pregnant women’s partners perceptions of professional support during pregnancy
  11. 3591
    “…The dimerization of EGFR and HER2 is associated with poor prognosis such as induction of tumor growth and cell invasion compared to when EGFR remains as a homodimer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1-dependent ACTA2 induction
  12. 3592
    “…We observed a strong positive correlation between PSCA-protein expression and HER2/neu receptor status (p<0.001). PSCA did not provide prognostic information in the analyzed cohort. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression
  13. 3593
    Publicado 1841
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Second Annual Report of the Registrar-General of Births, Deaths, and Marriages in England. Presented to Both Houses of Parliament, by Command of Her Majesty
  14. 3594
    “…These results suggested that the mechanism underlying the synergistic efficacy of the triple-drug combination was attributable, at least in part, to the docetaxel-mediated apoptosis being promoted by enhanced inhibition of HER2-HER3-AKT signaling as well to the intratumor infiltration of mononuclear cells induced by anti-HER2 antibodies being enhanced by docetaxel.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model
  15. 3595
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    “It is good to take her early to the doctor” – mothers’ understanding of childhood pneumonia symptoms and health care seeking in Kilimanjaro region, Tanzania
  16. 3596
    “…BACKGROUND: Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive disease that makes up about 20% of all invasive breast cancers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis
  17. 3597
    “…BACKGROUND: This is a retrospective cross sectional study aimed to verify whether Multiplex Ligation-dependent Probe Amplification (MLPA), a quantitative molecular assay, may represent a valuable reflex test in breast cancer with equivocal HER2 expression by immunohistochemistry and HER2 gene signals/nucleus (s/n) ranging between 4.0 and 5.9 by in situ hybridization. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification
  18. 3598
    “…It is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER-2 Over expression. Expression of ER, PR and HER-2 plays an important role in therapeutic assessment of patients with breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review
  19. 3599
    “…Describe the efficacy and safety data relating to their use in HR+, HER2– advanced breast cancer. 3. Discuss the key side effects associated with CDK4/6 inhibitors along with considerations for adverse event management and patient monitoring. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
  20. 3600
    “…The mammalian target of rapamycin complex 1 (mTORC1) is an attractive target for HER-2 positive breast cancer therapy because of its key role in protein translation regulation, cell growth and metabolism. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients
Herramientas de búsqueda: RSS